MEDICIS AND IPSEN DECIDE TO FOCUS PARTNERSHIP FOR RELOXIN EXCLUSIVELY ON UNITED STATES, CANADA AND JAPAN

Ipsen and Medicis today announced that they will not pursue an agreement for the commercialization of Ipsen's botulinum toxin product, Reloxin, outside of the United States, Canada and Japan.

PipelineReview (http://www.pipelinereview.com/joomla/content/view/5119/118/)